Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
AI Sentiment
Highly Positive
8/10
as of 02-23-2026 2:49pm EST
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 126.6M | IPO Year: | 2022 |
| Target Price: | $15.80 | AVG Volume (30 days): | 148.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | -24.05 |
| 52 Week Low/High: | $3.94 - $8.29 | Next Earning Date: | 01-01-0001 |
| Revenue: | $3,554,061 | Revenue Growth: | -40.79% |
| Revenue Growth (this year): | 70% | Revenue Growth (next year): | -90.15% |
| P/E Ratio: | -4.96 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
COYA Breaking Stock News: Dive into COYA Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how COYA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "COYA Coya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.